X

SITC Conference Coverage 2020

SITC Conference Coverage 2020

More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

Neoadjuvant chemotherapy plus nivolumab resulted in a higher frequency of disease downstaging and lower frequency of upstaging compared with other therapies among patients with...

Cancer Therapy Advisor
11/12/2020
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted onco

11/17/2020
SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 14, 2020

The SITC is pleased to present scientific highlights from the Nov. 14, 2020, sessions of the 35th Anniversary Annual Meeting.

11/14/2020

SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 13, 2020

The SITC is pleased to present scientific highlights from the Nov. 13, 2020, sessions of the 35th Anniversary Annual Meeting.

11/13/2020
Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials, New Report from Cancer Research Institute Reveals

The CRI announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment.

11/11/2020
Pseudoprogression With Immunotherapy in Cervical Cancer

Pseudoprogression with ICIs was observed in a cohort of patients with recurrent cervical cancer, including early, delayed, and serial events, according to the results of a study presented at the...

Cancer Therapy Advisor
11/12/2020
SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 12, 2020

The Society for Immunotherapy of Cancer (SITC) is pleased to present scientific highlights from the Nov. 12, 2020, sessions of the 35th Anniversary Annual Meeting.

11/12/2020
SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 11, 2020

The Society for Immunotherapy of Cancer (SITC) is pleased to present scientific highlights from the Nov. 11, 2020, sessions of the 35th Anniversary Annual Meeting.

11/11/2020
DLL3-Targeted BiTE Shows Antitumor Activity in SCLC

An anti-DLL3 bispecific T-cell engager demonstrated antitumor activity with an acceptable safety profile, according to interim results of a phase 1 study presented at the virtual... 

Cancer Therapy Advisor
11/13/2020
G-CSF Pretreatment Ameliorates the Activity of an Autologous DC-Based Vaccine in Melanoma

Pretreatment with granulocyte colony stimulating factor failed to improve dendritic cell collection for an autologous DC-based vaccine for advanced, resectable melanoma...

Cancer Therapy Advisor
11/13/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39